GT Biopharma, Inc. (GTBP) Revenue by Segment & Business Profile
Clinical-stage therapies for hematologic cancers was 100.0% of GT Biopharma, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GTBPGT Biopharma, Inc.Follow GTBP — free
—
Price chart with a free account
- Market cap
- 9.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
What the company does
GT Biopharma, Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $0 as of 2026-06-30.
Roles we read
from the filings, not the sector label- Biologics / biotech major
GT Biopharma, Inc. — questions
- What does GT Biopharma, Inc. do?
- GT Biopharma, Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $0 as of 2026-06-30.
- How does GT Biopharma, Inc. make money?
- By the lines it reports in its SEC filings: Clinical-stage therapies for hematologic cancers 100.0% of revenue.
Every figure on this page comes from GT Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.